BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

LibiGel testosterone: Phase III ongoing

For a fifth time, a DMC recommended continuation of a double-blind, placebo-controlled, international Phase III safety trial evaluating transdermal LibiGel for 12 months based on a review of unblinded safety data. Data from 2,869 evaluable patients showed that the rates of cardiovascular and...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >